According to filings with the U.S. Securities and Exchange Commission, Carlsmed is raising up to $52,499,996.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Michael Cordonnier played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Carlsmed
Carlsmeds mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The companys aprevo devices are designed to improve the standard of care for surgical treatment of patients with adult spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create optimal surgical plans and personalized aprevo spine fusion devices for each patient. The Carlsmed aprevo devices are FDA cleared and have been granted FDA Breakthrough Designation, an industry first for any implanted device, and are commercially available in the U.S.

To learn more about Carlsmed, visit http://carlsmed.com/

Contact:
Michael Cordonnier, Chief Executive Officer
858-295-9290
https://www.linkedin.com/in/mikecordonnier/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.